Oslo, January 23, 2019.
Bionor is pleased to announce that Proof of Mechanism is established for our 3rd vaccine candidate, CRX.
This product aims to prevent binding between gp120 V3 loop and CCR5/CXCR4 coreceptors and facilitate virus neutralization.
Lead optimization and drug characterization with Proof of Principle will be established within the next 6 – 9 months.
Bionor’s mission is to identify a functional cure for HIV through the use of two or more vaccines and the immune system. Bionor is the first company, which has successfully completed clinical trials and created a combination of therapeutic vaccines towards a functional cure. The company believes it has the first-mover advantage based on clinical results to date on Vacc-4x, Vacc-C5, and CRX.